CN1225464C - Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine - Google Patents
Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine Download PDFInfo
- Publication number
- CN1225464C CN1225464C CN 200310110337 CN200310110337A CN1225464C CN 1225464 C CN1225464 C CN 1225464C CN 200310110337 CN200310110337 CN 200310110337 CN 200310110337 A CN200310110337 A CN 200310110337A CN 1225464 C CN1225464 C CN 1225464C
- Authority
- CN
- China
- Prior art keywords
- wogonin
- injection
- oil
- agent
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to high-purity wogonin, a medical composition thereof, a preparation method thereof and an application thereof. The high-purity wogonin contains more than 90% of the wogonin measured by weight percentage, and additionally contains the compounds of baicalein, mica element, chrysin, etc. The wogonin of the present invention and the medical composition thereof are clinically used for treating various kinds of virus infection and diseases, such as hepatitis, virus common cold, acute respiratory tract syndrome caused by the virus infection, etc.
Description
Technical field
The present invention relates to effective ingredient in Chinese, pharmaceutical composition and preparation method and purposes, specifically, the present invention relates to highly purified wogonin, pharmaceutical composition and extraction process and medicinal use.
Background technology
Root of large-flowered skullcap The Chemical Constituents is of long duration, Chinese scholars has been carried out systematic research to its chemical ingredients and pharmacological action, therefrom separate the flavonoid compound that obtains baicalin (baicalin) is arranged, wogonoside (wogonside), scutellarin (baicalein), wogonin (wogonin), qroxylin A (oroxylinA), skullcapflavone I (skullcapflavoneI), and skullcapflavone II (skullcapflavoneII) etc., mainly contain baicalin in its root, noroxylin, (the resource science research of the medicinal root of large-flowered skullcap of Song's ten thousand will of multiple flavones ingredients such as wogonoside unit.Acta Pharmaceutica Sinica 1981,16 (2): 139～145).
Flavones ingredient in the root of large-flowered skullcap has stronger pharmacologically active.Scutellarin (also claims noroxylin, baicalein) proved conclusively have antibacterial, diuresis, anti-inflammatory resistance attitude activity, wogonin is antibacterial except that having, the diuresis, spasmolysis, and proof has stronger (the nearest progress of Ceng Guangfang natural flavonoid Shanghai medicine institute of the Chinese Academy of Sciences, 1963) such as antitumous effects.
Summary of the invention
One of purpose of the present invention provides a kind of highly purified wogonin.Highly purified wogonin of the present invention, have 5, the flavonoid compound of 7-dihydroxyl-8-methoxy flavone structure, wherein to count by weight percentage be more than 90% to the content of wogonin, also contains content and count by weight percentage and be lower than 10% scutellarin, oroxylin and chrysin compound.
Two of purpose of the present invention provides a kind of method for preparing above-mentioned highly purified wogonin.
Three of purpose of the present invention provide above-mentioned highly purified wogonin and pharmaceutically the acceptable pharmaceutical carrier mix to form pharmaceutical composition, can be used for the disease of the various virus infectiones of clinical treatment.
Four of purpose of the present invention provide above-mentioned highly purified wogonin with and the medicinal use of pharmaceutical composition.
For realizing above-mentioned goal of the invention, the present invention is by adopting following technical scheme.
A kind of highly purified wogonin, have 5, the flavonoid compound of 7-dihydroxyl-8-methoxy flavone structure, wherein to count by weight percentage be more than 90% to the content of wogonin, also contains content and count by weight percentage and be lower than 10% scutellarin, oroxylin and chrysin compound.
A kind of pharmaceutical composition is mixed to form composition with acceptable pharmaceutical carrier pharmaceutically by above-mentioned described wogonin; Preferred this pharmaceutical composition is tablet, capsule, soft capsule, sprays, gelifying agent, gel inhalation, oral preparation, suspensoid, electuary, patch, ointment, pill, powder, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, sustained release preparation or controlled release preparation; Described tablet or capsule are preferably the conventional tablet or the capsule of described wogonin and weighting agent or disintegrating agent assembly; Described sustained release preparation is preferably the slow releasing tablet or the slow releasing capsule of described wogonin and weighting agent and hypromellose K4M assembly; Described soft capsule is preferably described wogonin and is scattered in the soft capsule that obtains in the oil phase; Described ointment preferably prepares with the micro mist of described wogonin.Described injection is preferably injection or the suspension type injection liquid that described wogonin and solubilizing agent or solubility promoter form; Described freeze dried injection is preferably the freeze-drying injection powder pin of described wogonin and S-WAT formation.
Above-mentioned weighting agent is preferably lactose, Microcrystalline Cellulose, dextrin, starch or calcium phosphate; Disintegrating agent is preferably hydroxypropylcellulose, sodium starch glycolate, polyvinylpolypyrrolidone or croscarmellose sodium; Optional tackiness agent, wetting agent and the lubricant of adding.
Wherein, described tablet or capsule are formed by following prescription: described wogonin: lactose or Microcrystalline Cellulose: hydroxypropylcellulose or sodium starch glycolate, by weight calculating is 1: 0.5～5.0: 0.3～1.5, be preferably 1: 2.0～4.0: 0.7～and 1.3; Perhaps be described wogonin: lactose or Microcrystalline Cellulose: hypromellose K4M is 1: 0.5～2.5: 0.5～5.0 by weight calculating, be preferably 1: 0.7～1.5: 1.0～and 2.0.
Wherein, described soft capsule, used oil phase is preferably soybean oil, poly(oxyethylene glycol) 400, Oleum Gossypii semen, peanut oil, sesame oil, Semen Maydis oil or sweet oil; Also can add solubilizing agent or latent solvent or oxidation inhibitor.
Wherein, described injection, used solubilizing agent are preferably Soxylat A 25-7 Viscotrol C, tween or pluronic F-68; Used solubility promoter is preferably S-WAT, urea, niacinamide, proline(Pro), glucose, Citric Acid or its sodium salt.
Wherein, described suspension type injection liquid, preferred embodiment be with the micro mist of described wogonin and Polysorbate 80 mix grind after, be dissolved into the aqueous solution of phosphoric acid potassium dihydrogen, dipotassium hydrogen phosphate, nipagin esters and Xylo-Mucine, make through grinding.
Above-mentioned described highly purified wogonin, be to prepare by following method: radix scutellariae medicinal materials with water-wet after in 20～30 ℃ the insulation 12～24 hours, with solvent 1 refluxing extraction, extracting solution concentrates the back with 70～100% alcohol reflux, and most of extract is dissolved; Leaching insolubles, mother liquor with solvent 2 or solvent 3 wash-outs, are collected the yellow band of second with silica gel column chromatography or polyamide column chromatography, promptly obtain wogonin; Solvent 1 wherein is ethanol, ethyl acetate, acetone or its combination, and solvent 2 is sherwood oil, chloroform, ethyl acetate, acetone or its mixed solution, and solvent 3 is mixed solution, chloroform and the alcoholic acid mixed solution of ethanol and water or the mixed solution of chloroform and acetone etc.
Pharmaceutical combination preparation of the present invention can be made various dosage forms, comprise tablet, capsule, soft capsule, sprays, gelifying agent, gel inhalation, oral preparation, suspensoid, electuary, patch, ointment, pill, powder, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, sustained release preparation, controlled release preparation.Preferably tablet, capsule, slow releasing tablet and capsule, soft capsule, injection, freeze dried injection, suspensoid injectio, ointment.
Pharmaceutical composition of the present invention is characterised in that: the conventional tablet or the capsule that can be wogonin and weighting agent, disintegrating agent assembly; Or the slow releasing tablet or the capsule of wogonin and weighting agent and hypromellose K4M assembly; Wherein weighting agent can be selected lactose, Microcrystalline Cellulose, dextrin, starch, calcium phosphate etc. for use; Disintegrating agent can be selected hydroxypropylcellulose, sodium starch glycolate, polyvinylpolypyrrolidone, croscarmellose sodium etc. for use; Also optional tackiness agent, wetting agent and the lubricant of adding.
Preparation of pharmaceutical compositions tablet of the present invention or capsule prescription consist of: by weight, and wogonin 1: lactose or Microcrystalline Cellulose 0.5～5.0: hydroxypropylcellulose or sodium starch glycolate 0.3～1.5; Perhaps, wogonin 1: lactose or Microcrystalline Cellulose 0.5～2.5: hypromellose K4M0.5～5.0.
Preferred prescription is: by weight, and wogonin 1: lactose or Microcrystalline Cellulose 2.0～4.0: hydroxypropylcellulose or sodium starch glycolate 0.7～1.3; Perhaps, wogonin 1: lactose or Microcrystalline Cellulose 0.7～1.5: hypromellose K4M1.0～2.0.
Above-mentioned auxiliary material also can be selected for use, and disintegrating agent is as hydroxypropylated starch, hydroxypropylcellulose, sodium starch glycolate, calcium carboxymethylcellulose, polyvinylpolypyrrolidone, croscarmellose sodium etc.; Weighting agent is as lactose, sucrose, N.F,USP MANNITOL, Microcrystalline Cellulose, dextrin, starch, calcium phosphate, secondary calcium phosphate, calcium sulfate, lime carbonate, cyclodextrin, micro mist Mierocrystalline cellulose etc.; Wetting agent and tackiness agent are as pregelatinized Starch, polyvidone, Xylo-Mucine, hypromellose; Lubricant is as talcum powder, stearic acid, Magnesium Stearate, calcium stearate, micropowder silica gel, hydrogenated vegetable oil, Macrogol 4000 and 6000; Wetting agent is as sodium lauryl sulphate, tween 80; Framework material is as hypromellose, ethyl cellulose etc.
Medicinal composition soft capsule of the present invention is characterized in that: will make in wogonin dispersion and the oil phase.Wherein oil phase can be soybean oil, Oleum Gossypii semen, peanut oil, sesame oil, Semen Maydis oil, olive wet goods; Also can add solubilizing agent or latent solvent and oxidation inhibitor etc.
Soft capsule of the present invention also can be selected following auxiliary material for use: solvent is as poly(oxyethylene glycol) 400, Oleum Gossypii semen, peanut oil, sesame oil, Semen Maydis oil, olive wet goods; Solubilizing agent or latent solvent are as tween 80, Soxylat A 25-7 Viscotrol C, peruscabin, ethyl lactate etc.; Oxidation inhibitor is as Tenox PG, t-butyl phenol (BHT), vitamin-E etc.The ratio of gelatin, glycerine and water can suitably be regulated in the glue shell, is advisable 1: 0.3～0.4: 0.7～1.4 as gelatin/glycerin/water three's ratio, also can add other compositions in the glue shell, as sanitas: P-hydroxybenzoic acid first, second, third, butyl ester etc.; Softening agent such as sorbyl alcohol etc.; Stablizer such as gum arabic etc.; Opalizer is as titanium dioxide, barium sulfate, precipitated calcium carbonate etc.
Drug combination injection of the present invention is characterised in that: with the Injectable solution of wogonin and solubilizing agent or solubility promoter formation.Solubilizing agent can be selected Soxylat A 25-7 Viscotrol C, tween, pluronic F-68, polyvidone, polyoxyethylene glycol etc. for use; Solubility promoter can be selected S-WAT, potassium primary phosphate, urea, niacinamide, proline(Pro) for use, glucose, Citric Acid and sodium salt thereof etc.
The present invention can also form the injection freeze-dried powder with wogonin and S-WAT.
Medicinal-composition suspension type injection liquid of the present invention is characterized in that: with wogonin micro mist and Polysorbate 80 mix grind after, be dissolved into the aqueous solution of phosphoric acid potassium dihydrogen, dipotassium hydrogen phosphate, nipagin esters and Xylo-Mucine, make through grinding.
Injection of the present invention also can be selected following auxiliary material for use: solubilizing agent is as Tweens, pluronic F-68, polyoxyethylene glycol, Soxylat A 25-7 Viscotrol C, polyvidone etc.; Solubility promoter is as sodium bisulfite, yellow soda ash, sodium bicarbonate, potassium primary phosphate, primary ammonium phosphate etc.; Amides such as urea, ethanamide, thiocarbamide, benzamide etc., amino acids such as arginine, aspartic acid, Serine, glycine, methionine(Met), Histidine, L-glutamic acid, Isoleucine, Threonine, halfcystine, Gelucystine, tryptophane, phenylalanine, Methionin, the compound of hydroxyl or carboxyl such as sucrose, glucose, fructose, wood sugar, seminose, Citric Acid and sodium salt thereof, lactic acid, sodium salicylate etc.; Suspending agent is as Xylo-Mucine, polyvidone, HPMC etc.; Sanitas is as: Metagin, second, third and butyl ester; The pH regulator agent is as Citric Acid and citrate, phosphoric acid salt etc.; Oxidation inhibitor is as vitamins C, cysteine hydrochloride etc.; Solvent is as water for injection, injection ethanol, propylene glycol etc.
Pharmaceutical composition ointment of the present invention is characterized in that: prepare ointment with the wogonin micro mist.
Every or every of medicinal compositions preferred oral formulation of the present invention contains wogonin 20-60mg, and every of injection contains 10mg.
The amount of application of formula of the present invention (I) medicinal compositions can be according to variations such as the type of route of administration, patient age, body weight, body surface area, the disease of being treated and severity, and its per daily dose can be 80-3600mg, preferred 120-240mg.Can use by one or many.
Above-mentioned described high-purity wogonin of the present invention and described pharmaceutical composition can be used for various virus infections, preferably use in the medicine of acute respiratory syndrome that preparation treatment hepatitis, viral cold, virus infection cause etc.
Embodiment
For a better understanding of the present invention, further set forth the present invention, but should not be understood that the present invention is had any restriction below by specific embodiment.
Embodiment 1
Get radix scutellariae medicinal materials 20kg and be ground into meal, add water-wet, and, use alcohol reflux three times in 20～30 ℃ of incubated overnight.Decompression recycling ethanol does not steam to there being ethanol, resistates adds 85% ethanol, and heating makes most of dissolving, filters, filtrate is with column chromatography silica gel, separate with column chromatography,, collect the yellow band of second with sherwood oil and 1: 3 wash-out of chloroform, promptly get the about 100g of wogonin, through purity test, be mainly wogonin (content is greater than 90%), also contain a small amount of scutellarin, oroxylin and chrysin compound (content is less than 10%).
Embodiment 2
Get radix scutellariae medicinal materials 20kg and be ground into meal, add water-wet, and, extract three times with ethyl acetate backflow in 20～30 ℃ of incubated overnight.Reclaim under reduced pressure does not steam to there being ethyl acetate, resistates adds 75% ethanol, heating makes most of dissolving, filters, and filtrate is separated with polyamide column chromatography, use ethanol: the water gradient elution, collect the second colour band, promptly get the about 100g of wogonin, through purity test, be mainly wogonin (content is greater than 90%), also contain a small amount of scutellarin, oroxylin and chrysin compound (content is less than 10%).
Embodiment 3
The preparation of wogonin capsule
Prescription: wogonin 20mg
Lactose 60mg
Microcrystalline Cellulose 60mg
Hydroxypropylcellulose 20mg
Polysorbate 80 16mg
3% HPMC (E5) aqueous solution is an amount of
Talcum powder 2.5mg
Wogonin, lactose, Microcrystalline Cellulose, hydroxypropylcellulose are crossed 60 mesh sieves be mixed, add an amount of Polysorbate 80, add 3% HPMC (E5) aqueous solution and make softwood in right amount, cross 20 mesh sieves and granulate.40-50 ℃ of baking oven forced air drying.Dried particle is crossed the whole grain of 20 mesh sieves, adds the talcum powder of recipe quantity, mixes.Press No. 1 capsule of recipe quantity can, every contains wogonin 20mg.Usage: every day three times, each two.
Embodiment 4
The preparation of wogonin tablet
Prescription: wogonin 20mg
Lactose 60mg
Microcrystalline Cellulose 60mg
Hydroxypropylcellulose 20mg
Polysorbate 80 16mg
3% HPMC (E5) aqueous solution is an amount of
Talcum powder 2.5mg
Wogonin, lactose, Microcrystalline Cellulose, hydroxypropylcellulose are crossed 60 mesh sieves be mixed, add an amount of Polysorbate 80, add 3% HPMC (E5) aqueous solution and make softwood in right amount, cross 20 mesh sieves and granulate.40-50 ℃ of baking oven forced air drying.Dried particle is crossed the whole grain of 20 mesh sieves, adds the talcum powder of recipe quantity, mix, and compressing tablet, every contains wogonin 20mg.Usage: every day three times, each two.
Embodiment 5
The preparation of wogonin slow releasing capsule
Prescription: wogonin 60mg
Microcrystalline Cellulose 60mg
Hypromellose K4M 100mg
3% HPMC (E5) aqueous solution is an amount of
Talcum powder 4mg
Wogonin, Microcrystalline Cellulose, hypromellose K4M are crossed 60 mesh sieves and be mixed, add 3% HPMC (E5) aqueous solution and make softwood in right amount, cross 20 mesh sieves and granulate.40-50 ℃ of baking oven forced air drying.Dried particle is crossed the whole grain of 20 mesh sieves, adds the talcum powder of recipe quantity, mixes.Press recipe quantity can capsule, every contains wogonin 60mg.Usage: every day secondary, each one.
Embodiment 6
The preparation of wogonin slow releasing tablet
Prescription: wogonin 60mg
Lactose 60mg
Hypromellose K4M 100mg
3% HPMC (E5) aqueous solution is an amount of
Talcum powder 4mg
Wogonin, lactose, hypromellose K4M are crossed 60 mesh sieves and be mixed, add 3% HPMC (E5) aqueous solution and make softwood in right amount, cross 20 mesh sieves and granulate.40-50 ℃ of baking oven forced air drying.Dried particle is crossed the whole grain of 20 mesh sieves, adds the talcum powder of recipe quantity, mix, and compressing tablet, every contains wogonin 60mg.Usage: every day secondary, each a slice.
Embodiment 7
The wogonin soft capsule
Prescription: every of content contains the glue shell
Wogonin 20mg gelatin 46.00%
PEG400 0.5ml glycerine 17.82%
Water 36.18%
Get wogonin and be dissolved among the PEG400, this solution is made soft capsule.Every contains wogonin 20mg.
Embodiment 8
The wogonin injection
Prescription: wogonin 10mg
Soxylat A 25-7 Viscotrol C 1.0mg
Dehydrated alcohol 5.0mg
Water for injection adds to 5.0mL
Wogonin is dissolved in dehydrated alcohol, add Soxylat A 25-7 Viscotrol C (CremophorELP), mixing, reduction vaporization is removed ethanol, add an amount of water for injection and be mixed into clear solution, through 0.22 μ m filtering with microporous membrane, coating-dividing sealing, in 100 ℃ of flowing steam sterilizations 30 minutes promptly, every contains wogonin 10mg.
Embodiment 9
The wogonin injection
Prescription: wogonin 1.0g
S-WAT 1.0g
Ethanol 50mL
Water for injection adds to 1000mL
Wogonin and S-WAT are dissolved in the ethanol, under ultrasonic or agitation condition, add the water for injection mixing gradually and make into clear solution; Through 0.22 μ m filtering with microporous membrane, coating-dividing sealing, in 100 ℃ of flowing steam sterilizations 30 minutes promptly, every contains wogonin 10mg.
Embodiment 10
The wogonin injection
Prescription: wogonin 1.0g
Niacinamide 2.0g
Ethanol 200mL
Water for injection adds to 1000mL
Wogonin and niacinamide are dissolved in the ethanol, under ultrasonic or agitation condition, add the water for injection mixing gradually and make into clear solution; Through 0.22 μ m filtering with microporous membrane, coating-dividing sealing, in 100 ℃ of flowing steam sterilizations 30 minutes promptly, every contains wogonin 10mg.
Embodiment 11
Injection wogonin (powder injection)
Prescription: wogonin 10mg
S-WAT 10mg
Polyvidone 50mg
N.F,USP MANNITOL 50mg
Wogonin and S-WAT are dissolved in 50% ethanol, add polyvidone and make dissolving; Solvent removed by evaporation at reduced pressure is taken out under aseptic condition, to the electric vacuum drying oven inner drying, pulverizes the back and mixes with N.F,USP MANNITOL, and packing promptly.Every contains wogonin 10mg.
Embodiment 12
Wogonin suspension type injection
Prescription: wogonin 10mg
Xylo-Mucine 10mg
Polysorbate 80 0.1mg
Ethyl p-hydroxybenzoate 0.5mg
Propylben 0.5mg
Potassium primary phosphate 16.7mg
Dipotassium hydrogen phosphate 1.7mg
Water for injection adds to 2ml
Wogonin is carried out comminution by gas stream, get the following micro mist of particle diameter 10 μ m.Potassium primary phosphate and dipotassium hydrogen phosphate are dissolved in the water for injection, add ethyl p-hydroxybenzoate and propyl ester, add Xylo-Mucine again, make whole dissolvings under 60 ℃ of conditions.Wogonin after the micronization is placed container, add Polysorbate 80 and be ground into thin pasty state, above-mentioned solution is added gradually, after stirring, grind 5 to 10 times through colloidal mill.Routinely measuring method measure content qualified after, be divided in the ampoule, in 100 ℃ of flowing steam sterilizations 30 minutes promptly, every contains wogonin 10mg.
Embodiment 13
Wogonin ointment
Prescription: wogonin 50g
Glyceryl monostearate 120g
Paraffin 50g
Beeswax 50g
White vaseline 50g
Whiteruss 250g
Sorbester p17 20g
Tween 80 10g
Ethyl p-hydroxybenzoate 1g
Distilled water adds to 1000g
Wogonin ground be impalpable powder, prepare O/W type emulsifiable paste by emulsion process.
Claims (13)
1, a kind of highly purified wogonin, have 5, the flavonoid compound of 7-dihydroxyl-8-methoxy flavone structure, wherein to count by weight percentage be more than 90% to the content of wogonin, also contains content and count by weight percentage and be lower than 10% scutellarin, oroxylin and chrysin compound.
2, a kind of pharmaceutical composition is characterized in that the described wogonin of claim 1 mixes with acceptable pharmaceutical carrier pharmaceutically to form composition.
3, the pharmaceutical composition of claim 2 is tablet, capsule, soft capsule, sprays, gelifying agent, gel inhalation, oral preparation, suspensoid, electuary, patch, ointment, pill, powder, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, sustained release preparation or controlled release preparation.
4, described tablet of claim 3 or capsule are the conventional tablet or the capsule of described wogonin and weighting agent or disintegrating agent assembly; Described sustained release preparation is the slow releasing tablet or the slow releasing capsule of described wogonin and weighting agent and hypromellose K4M assembly; Described soft capsule is that described wogonin is scattered in the soft capsule that obtains in the oil phase; Described ointment is that the micro mist with described wogonin prepares; Described injection is the injection or the suspension type injection liquid of described wogonin and solubilizing agent or solubility promoter formation; Described freeze dried injection is the freeze-drying injection powder pin that described wogonin and S-WAT form.
5, the described weighting agent of claim 4 is selected from lactose, Microcrystalline Cellulose, dextrin, starch and calcium phosphate; Described disintegrating agent is selected from hydroxypropylcellulose, sodium starch glycolate, polyvinylpolypyrrolidone and croscarmellose sodium; Optional tackiness agent, wetting agent and the lubricant of adding.
6, the described pharmaceutical composition of claim 5, wherein said wogonin: lactose or Microcrystalline Cellulose: hydroxypropylcellulose or sodium starch glycolate are 1: 0.5～5.0: 0.3～1.5 by weight calculating.
7, the described pharmaceutical composition of claim 6, wherein said wogonin: lactose or Microcrystalline Cellulose: hydroxypropylcellulose or sodium starch glycolate are 1: 2.0～4.0: 0.7～1.3 by weight calculating.
8, the described pharmaceutical composition of claim 5, wherein said wogonin: lactose or Microcrystalline Cellulose: hypromellose K4M is 1: 0.5～2.5: 0.5～5.0 by weight calculating.
9, the described pharmaceutical composition of claim 8, wherein said wogonin: lactose or Microcrystalline Cellulose: hypromellose K4M is 1: 0.7～1.5: 1.0～2.0 by weight calculating.
10, the used oil phase of the described soft capsule of claim 4 is selected from soybean oil, poly(oxyethylene glycol) 400, Oleum Gossypii semen, peanut oil, sesame oil, Semen Maydis oil and sweet oil; The used solubilizing agent of described injection is selected from Soxylat A 25-7 Viscotrol C, tween and pluronic F-68, and used solubility promoter is selected from S-WAT, urea, niacinamide, proline(Pro), glucose, Citric Acid and sodium salt thereof; Described suspension type injection liquid be with the micro mist of described wogonin and Polysorbate 80 mix grind after, be dissolved into the aqueous solution of phosphoric acid potassium dihydrogen, dipotassium hydrogen phosphate, nipagin esters and Xylo-Mucine, make through grinding.
11, the used oil phase of the described soft capsule of claim 4 is selected from soybean oil, poly(oxyethylene glycol) 400, Oleum Gossypii semen, peanut oil, sesame oil, Semen Maydis oil and sweet oil, and also adds solubilizing agent or latent solvent or oxidation inhibitor.
12, the extraction process of the described wogonin of a kind of claim 1, radix scutellariae medicinal materials with water-wet after in 20～30 ℃ of insulations 12～24 hours, with solvent 1 refluxing extraction, extracting solution concentrates the back with 70～100% alcohol reflux, and most of extract is dissolved; Leaching insolubles, mother liquor with solvent 2 or solvent 3 wash-outs, are collected the yellow band of second with silica gel column chromatography or polyamide column chromatography, promptly obtain wogonin; Solvent 1 wherein is ethanol, ethyl acetate, acetone or its combination, and solvent 2 is sherwood oil, chloroform, ethyl acetate, acetone or its mixed solution, and solvent 3 is mixed solution, chloroform and the alcoholic acid mixed solution of ethanol and water or the mixed solution of chloroform and acetone.
13, among the claim 1-8 any one in the medicine of the acute respiratory syndrome that preparation treatment hepatitis, viral cold, virus infection cause, use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110337 CN1225464C (en) | 2003-12-31 | 2003-12-31 | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310110337 CN1225464C (en) | 2003-12-31 | 2003-12-31 | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1556101A CN1556101A (en) | 2004-12-22 |
| CN1225464C true CN1225464C (en) | 2005-11-02 |
Family
ID=34335585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310110337 Expired - Fee Related CN1225464C (en) | 2003-12-31 | 2003-12-31 | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1225464C (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325048C (en) * | 2005-11-09 | 2007-07-11 | 中国药科大学 | Application of wogonin for preparing medicine to treat or prevent hepatitis B |
| CN102516301B (en) * | 2011-11-28 | 2016-08-03 | 江苏天地人和药业有限公司 | Wogonin derivant for treatment |
| CN102525929A (en) * | 2012-02-23 | 2012-07-04 | 中国药科大学 | Wogonin liposome preparation modified with glycyrrhetinic acid and preparation method thereof |
| CN103933002A (en) * | 2014-05-06 | 2014-07-23 | 鲁南制药集团股份有限公司 | Scutellaria baicalensis total flavonoid sustained release tablet and preparation method thereof |
| CN104258402B (en) * | 2014-09-28 | 2017-01-11 | 青岛橡胶谷知识产权有限公司 | Wogonin composition and preparation method thereof |
| CN107648310B (en) * | 2016-07-24 | 2021-05-04 | 复旦大学 | High-purity scutellaria total flavone, its preparation method and medicinal application |
| CN108992672B (en) * | 2017-06-07 | 2022-08-09 | 山东丹红制药有限公司 | Wogonin pharmaceutical composition for treating tumor |
| CN107714689A (en) * | 2017-10-13 | 2018-02-23 | 常州市武进人民医院 | Application of the wogonin in anti-herpes simplex virus medicament is prepared |
| CN107595706A (en) * | 2017-10-18 | 2018-01-19 | 森知（上海）国际贸易有限公司 | A kind of skin conditioning composition |
| CN111329896A (en) * | 2020-01-19 | 2020-06-26 | 中国药科大学 | Anti-influenza pharmaceutical composition and application thereof |
-
2003
- 2003-12-31 CN CN 200310110337 patent/CN1225464C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1556101A (en) | 2004-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1091368C (en) | Pharmaceutical composition comprising coenzyme Q10 | |
| CN1245398C (en) | Extraction technology of baicalein, medicinal composition and preparation technology of medicine | |
| CN1219879A (en) | Pharmaceutical compositions | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1778391A (en) | Safety and high-efficient compound hypolipidemic medicine | |
| CN1846729A (en) | New film prepn form capable of being dissolved fast in oral cavity and its prepn process | |
| CN1810284A (en) | Yunnan Rhizoma Paridis extract and its prepn, medicinal use and medicine composition | |
| CN1695624A (en) | Combination of medication of containing kurarinone and glycyrrhetic acid, and application | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1404831A (en) | Use of Radix scutellariae glycoside in preparing medicine for treating prostatic disorders and its medicinal composition | |
| CN1486699A (en) | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine | |
| CN1680390A (en) | Halogenated dihydroartemisine, preparation and use thereof | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1911251A (en) | Traditional Chinese medicine enteric oral liquor using fresh earthworm extractive as active component, and its prepn. method | |
| CN1295231C (en) | Bromo-dihydroartemisine | |
| CN1762362A (en) | Medicinal composition with red sage root component for treating cardiovascular and cerebrovascular disease and its application | |
| CN1267094C (en) | Orally disintegrating tablet of safflor yellow and its preparation process | |
| CN1682730A (en) | Cepharanthine slow releasing preparation | |
| CN1296042C (en) | Acetyl salicyl sulfonone oral cavity disintegration tablet and its preparation method | |
| CN1923191A (en) | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases | |
| CN1535972A (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| CN1297260C (en) | Fatty acyl acetaldehyde powder projection and its preparing method | |
| CN101062040A (en) | Stable type cucurbitacin liquid formula and the agent thereof | |
| CN1562060A (en) | Haw leaf total flavone oral disintegration tablet and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051102 Termination date: 20100201 |